IS6902A - N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl - Google Patents
N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýlInfo
- Publication number
- IS6902A IS6902A IS6902A IS6902A IS6902A IS 6902 A IS6902 A IS 6902A IS 6902 A IS6902 A IS 6902A IS 6902 A IS6902 A IS 6902A IS 6902 A IS6902 A IS 6902A
- Authority
- IS
- Iceland
- Prior art keywords
- aryl
- substituted heterocyclic
- nr2b antagonists
- nmda
- heterocyclic nmda
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27110001P | 2001-02-23 | 2001-02-23 | |
| PCT/US2002/005226 WO2002068409A1 (en) | 2001-02-23 | 2002-02-20 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6902A true IS6902A (is) | 2003-07-31 |
Family
ID=23034191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6902A IS6902A (is) | 2001-02-23 | 2003-07-31 | N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7217716B2 (is) |
| EP (1) | EP1379520B2 (is) |
| JP (1) | JP4179879B2 (is) |
| KR (1) | KR100849839B1 (is) |
| CN (1) | CN100567293C (is) |
| AT (1) | ATE324371T1 (is) |
| AU (1) | AU2002252053B2 (is) |
| BG (1) | BG108113A (is) |
| BR (1) | BR0207526A (is) |
| CA (1) | CA2438895A1 (is) |
| CZ (1) | CZ20032258A3 (is) |
| DE (1) | DE60210944T3 (is) |
| DK (1) | DK1379520T3 (is) |
| EA (1) | EA005974B1 (is) |
| EC (1) | ECSP034744A (is) |
| EE (1) | EE200300403A (is) |
| ES (1) | ES2261658T3 (is) |
| GE (1) | GEP20063741B (is) |
| HR (1) | HRP20030669A2 (is) |
| HU (1) | HUP0303258A3 (is) |
| IL (2) | IL157254A0 (is) |
| IS (1) | IS6902A (is) |
| MX (1) | MXPA03007621A (is) |
| NO (1) | NO20033732L (is) |
| NZ (1) | NZ527365A (is) |
| PL (1) | PL364625A1 (is) |
| PT (1) | PT1379520E (is) |
| SI (1) | SI1379520T1 (is) |
| SK (1) | SK10542003A3 (is) |
| UA (1) | UA75392C2 (is) |
| WO (1) | WO2002068409A1 (is) |
| YU (1) | YU64303A (is) |
| ZA (1) | ZA200306159B (is) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2449249A1 (en) * | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| WO2003048140A1 (en) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003214110A1 (en) * | 2002-03-15 | 2003-09-29 | Ciba Specialty Chemicals Holding Inc. | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| WO2003087089A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| EP1505067A4 (en) | 2002-04-25 | 2006-06-21 | Teijin Ltd | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES WITH CCR3 ANTAGONISM |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| JP2004315511A (ja) * | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Ｍｃｈ受容体アンタゴニスト |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| KR20060017839A (ko) * | 2003-06-04 | 2006-02-27 | 머크 앤드 캄파니 인코포레이티드 | Ｎｍｄａ／ｎｒ2ｂ 길항제로서 3-플루오로-피페리딘 |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ATE413389T1 (de) | 2004-02-03 | 2008-11-15 | Astrazeneca Ab | Chinazolinderivate |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US20070293515A1 (en) * | 2004-08-03 | 2007-12-20 | Layton Mark E | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists |
| US20080153917A1 (en) * | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| ATE461190T1 (de) * | 2005-12-21 | 2010-04-15 | Janssen Pharmaceutica Nv | Substituierte pyradinon-derivate als alpha2- adrenorezeptor-antagonisten |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US20100273776A1 (en) * | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| BRPI0720003A2 (pt) * | 2006-12-08 | 2018-09-18 | Hoffmann La Roche | pirimidinas substituídas e seu uso como moduladores de jnk |
| JP5377332B2 (ja) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法 |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| RU2489431C2 (ru) | 2007-04-23 | 2013-08-10 | Янссен Фармацевтика Н.В. | Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2 |
| JP5431305B2 (ja) | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体 |
| BRPI0815591B8 (pt) * | 2007-08-22 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e, uso de um composto. |
| WO2009058261A1 (en) * | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| MX2010012442A (es) | 2008-05-13 | 2011-10-11 | Astrazeneca Ab | Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina. |
| JP5417439B2 (ja) | 2008-07-03 | 2014-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類 |
| EA019048B1 (ru) | 2008-07-31 | 2013-12-30 | Янссен Фармацевтика Нв | Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| AU2011218491C1 (en) * | 2010-02-18 | 2015-05-14 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| MX2012009537A (es) * | 2010-02-18 | 2012-08-31 | Astrazeneca Ab | Formas solidas que comprenden un derivado de ciclopropilamida. |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CA2831710A1 (en) * | 2011-03-31 | 2012-10-04 | Bayer Intellectual Property Gmbh | Substituted benzimidazoles as mps-1 kinase inhibitors |
| EP2760856B1 (en) * | 2011-09-30 | 2016-09-14 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| AU2013251079B2 (en) | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| JP2016028017A (ja) * | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| US9856250B2 (en) * | 2014-05-28 | 2018-01-02 | Toa Eiyo Ltd. | Substituted tropane derivatives |
| US10030026B2 (en) * | 2014-06-04 | 2018-07-24 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| MX2017002775A (es) * | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| WO2016100349A2 (en) * | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CN107592859A (zh) | 2015-05-11 | 2018-01-16 | 巴斯夫欧洲公司 | 制备4‑氨基哒嗪类的方法 |
| CA2987606C (en) | 2015-06-01 | 2024-02-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| JP7301862B2 (ja) * | 2018-02-23 | 2023-07-03 | フラウンホーファー－ゲゼルシャフト ツル フェルデルング デル アンゲヴァンテン フォルシュング エー ファウ | 歯周病及び関連疾患の治療に用いる細菌性グルタミニルシクラーゼの新規阻害剤 |
| KR20260110156A (ko) * | 2023-11-28 | 2026-07-14 | 챙도우 띠'야우 파마슈티칼 그룹 캄파니, 리미티드 | 질소 함유 헤테로고리 화합물, 이의 제조 방법 및 응용 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL265777A (is) | 1960-06-09 | |||
| DE2341965C3 (de) * | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
| US4197304A (en) * | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
| WO1984001151A1 (en) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
| HU222726B1 (hu) | 1990-02-06 | 2003-09-29 | Pfizer, Inc., | Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények |
| EP0554247B1 (en) | 1990-05-10 | 2000-04-26 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| US5189036A (en) | 1990-06-20 | 1993-02-23 | Schering Ag | Imidazolylbenzoyl substituted heterocycles |
| FI934566L (fi) | 1991-04-18 | 1993-10-15 | Pfizer | Prodrug-estrar av fenol-2-piperidino-1-alkanoler |
| AU655840B2 (en) | 1991-07-17 | 1995-01-12 | Pfizer Inc. | 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| US5436255A (en) | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ATE236882T1 (de) | 1992-12-21 | 2003-04-15 | Smithkline Beecham Corp | Bicyklische fibrinogen antagoniste |
| DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU6252794A (en) | 1993-03-03 | 1994-09-26 | Eli Lilly And Company | Balanoids |
| EP0689535B1 (en) | 1993-03-18 | 1998-09-23 | MERCK SHARP & DOHME LTD. | Benzimidazole derivatives |
| AU3138595A (en) | 1994-07-20 | 1996-02-16 | Acea Pharmaceuticals, Inc. | Haloperidol analogs and the use thereof |
| US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0742208A1 (en) | 1995-05-05 | 1996-11-13 | Grelan Pharmaceutical Co., Ltd. | 2-Ureido-benzamide derivatives |
| DK0828513T3 (da) | 1995-05-26 | 2004-04-13 | Pfizer | Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister |
| DE19541264A1 (de) | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| EP0771779B1 (en) | 1995-11-06 | 2002-05-02 | Kuraray Co., Ltd. | Process for producing acetals |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| EP0787493A1 (en) | 1996-02-03 | 1997-08-06 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline derivatives |
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| WO1997045119A1 (en) | 1996-05-24 | 1997-12-04 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| JP2000516596A (ja) | 1996-07-25 | 2000-12-12 | バイオジェン，インコーポレイテッド | 細胞接着インヒビター |
| DZ2285A1 (fr) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| EP0846683B1 (en) | 1996-12-03 | 2001-09-19 | F. Hoffmann-La Roche Ag | 4-Hydroxy-piperidine derivatives |
| FR2758327B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles arylpiperazines derivees de piperidine |
| FR2758328B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments |
| IT1291569B1 (it) | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| AU1415099A (en) | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| US6020347A (en) | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| DE19815026A1 (de) * | 1998-04-03 | 1999-10-07 | Hoechst Schering Agrevo Gmbh | Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| WO2000008015A2 (en) | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
| DE19838300A1 (de) | 1998-08-24 | 2000-03-02 | Bayer Ag | 9-Dialkylaminopurinon-derivate |
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| BR0009739A (pt) | 1999-04-13 | 2002-04-09 | Basf Ag | Composto, medicamento, preparação farmacêutica, e, usos de um elemento estrutural, de um composto e de uma preparação farmacêutica |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
-
2002
- 2002-02-20 MX MXPA03007621A patent/MXPA03007621A/es active IP Right Grant
- 2002-02-20 NZ NZ527365A patent/NZ527365A/en unknown
- 2002-02-20 SI SI200230322T patent/SI1379520T1/sl unknown
- 2002-02-20 YU YU64303A patent/YU64303A/sh unknown
- 2002-02-20 CN CNB028087135A patent/CN100567293C/zh not_active Expired - Fee Related
- 2002-02-20 PL PL02364625A patent/PL364625A1/xx not_active Application Discontinuation
- 2002-02-20 AT AT02721105T patent/ATE324371T1/de not_active IP Right Cessation
- 2002-02-20 JP JP2002567923A patent/JP4179879B2/ja not_active Expired - Fee Related
- 2002-02-20 ES ES02721105T patent/ES2261658T3/es not_active Expired - Lifetime
- 2002-02-20 WO PCT/US2002/005226 patent/WO2002068409A1/en not_active Ceased
- 2002-02-20 UA UA2003098659A patent/UA75392C2/uk unknown
- 2002-02-20 BR BR0207526-1A patent/BR0207526A/pt not_active IP Right Cessation
- 2002-02-20 EE EEP200300403A patent/EE200300403A/xx unknown
- 2002-02-20 IL IL15725402A patent/IL157254A0/xx active IP Right Grant
- 2002-02-20 SK SK1054-2003A patent/SK10542003A3/sk not_active Application Discontinuation
- 2002-02-20 US US10/470,561 patent/US7217716B2/en not_active Expired - Fee Related
- 2002-02-20 KR KR1020037011079A patent/KR100849839B1/ko not_active Expired - Fee Related
- 2002-02-20 DK DK02721105T patent/DK1379520T3/da active
- 2002-02-20 GE GE5284A patent/GEP20063741B/en unknown
- 2002-02-20 HR HR20030669A patent/HRP20030669A2/hr not_active Application Discontinuation
- 2002-02-20 AU AU2002252053A patent/AU2002252053B2/en not_active Ceased
- 2002-02-20 CZ CZ20032258A patent/CZ20032258A3/cs unknown
- 2002-02-20 PT PT02721105T patent/PT1379520E/pt unknown
- 2002-02-20 DE DE60210944.2T patent/DE60210944T3/de not_active Expired - Lifetime
- 2002-02-20 HU HU0303258A patent/HUP0303258A3/hu unknown
- 2002-02-20 EA EA200300919A patent/EA005974B1/ru not_active IP Right Cessation
- 2002-02-20 CA CA002438895A patent/CA2438895A1/en not_active Abandoned
- 2002-02-20 US US10/079,452 patent/US7053089B2/en not_active Expired - Lifetime
- 2002-02-20 EP EP02721105.1A patent/EP1379520B2/en not_active Expired - Lifetime
-
2003
- 2003-07-31 IS IS6902A patent/IS6902A/is unknown
- 2003-08-05 IL IL157254A patent/IL157254A/en not_active IP Right Cessation
- 2003-08-08 ZA ZA200306159A patent/ZA200306159B/en unknown
- 2003-08-19 BG BG108113A patent/BG108113A/bg unknown
- 2003-08-22 EC EC2003004744A patent/ECSP034744A/es unknown
- 2003-08-22 NO NO20033732A patent/NO20033732L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1379520T3 (da) | N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| ATE440603T1 (de) | 8-hydroxychinolinderivate | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| DE602006017694D1 (de) | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| NO20060774L (no) | Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| GB0426313D0 (en) | Therapeutic agents | |
| MX2009004426A (es) | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| MXPA05013151A (es) | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
| NO20052182L (no) | Nye forbindelser | |
| TW200726764A (en) | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| WO2004067703A3 (en) | 5ht7 antagonists and inverse agonists | |
| EA200401290A1 (ru) | НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa | |
| ATE338046T1 (de) | 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität | |
| TW200740442A (en) | Therapeutic agent for hypertension |